{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:39:30Z","timestamp":1792787970090,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T00:00:00Z","timestamp":1578268800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T00:00:00Z","timestamp":1578268800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"VEGA Grant Agency of the Slovak Republic","award":["2\/0108\/17"],"award-info":[{"award-number":["2\/0108\/17"]}]},{"name":"VEGA Grant Agency of the Slovak Republic","award":["2\/0053\/19"],"award-info":[{"award-number":["2\/0053\/19"]}]},{"name":"VEGA Grant Agency of the Slovak Republic","award":["1\/0043\/18"],"award-info":[{"award-number":["1\/0043\/18"]}]},{"DOI":"10.13039\/501100005357","name":"Slovak Research and Development Agency","doi-asserted-by":"crossref","award":["APVV-17-0384"],"award-info":[{"award-number":["APVV-17-0384"]}],"id":[{"id":"10.13039\/501100005357","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005357","name":"Slovak Research and Development Agency","doi-asserted-by":"crossref","award":["APVV-0016-11"],"award-info":[{"award-number":["APVV-0016-11"]}],"id":[{"id":"10.13039\/501100005357","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005357","name":"Slovak Research and Development Agency","doi-asserted-by":"crossref","award":["APVV-15-0086"],"award-info":[{"award-number":["APVV-15-0086"]}],"id":[{"id":"10.13039\/501100005357","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Ministry of Health of the Slovak Republic","award":["2019\/57-BMCSAV-1"],"award-info":[{"award-number":["2019\/57-BMCSAV-1"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Germ cell tumours (GCTs) represent a highly curable malignity as they respond well to cisplatin (CDDP)-based chemotherapy. Nevertheless, a small proportion of GCT patients relapse or do not respond to therapy. As this might be caused by an increased capacity to repair CDDP-induced DNA damage, identification of DNA repair biomarkers predicting inadequate or aberrant response to CDDP, and thus poor prognosis for GCT patients, poses a challenge. The objective of this study is to examine the expression levels of the key nucleotide excision repair (NER) factors, XPA, ERCC1 and XPF, in GCT patients and cell lines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Two hundred seven GCT patients\u2019 specimens with sufficient follow-up clinical-pathological data and pairwise combinations of CDDP-resistant and -sensitive GCT cell lines were included. Immunohistochemistry was used to detect the ERCC1, XPF and XPA protein expression levels in GCT patients\u2019 specimen and Western blot and qRT-PCR examined the protein and mRNA expression levels in GCT cell lines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      GCT patients with low\n                      <jats:italic>XPA<\/jats:italic>\n                      expression had significantly better overall survival than patients with high expression (hazard ratio\u2009=\u20090.38, 95% confidence interval: 0.12\u20131.23,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0228). In addition,\n                      <jats:italic>XPA<\/jats:italic>\n                      expression was increased in the non-seminomatous histological subtype, IGCCCG poor prognosis group, increasing S stage, as well as the presence of lung, liver and non-pulmonary visceral metastases. Importantly, a correlation between inadequate or aberrant CDDP response and\n                      <jats:italic>XPA<\/jats:italic>\n                      expression found in GCT patients was also seen in GCT cell lines.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      <jats:italic>XPA<\/jats:italic>\n                      expression is an additional independent prognostic biomarker for stratifying GCT patients, allowing for improvements in decision-making on treatment for those at high risk of refractoriness or relapse. In addition, it could represent a novel therapeutic target in GCTs.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-019-6496-1","type":"journal-article","created":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T11:02:43Z","timestamp":1578308563000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Increased levels of XPA might be the basis of cisplatin resistance in germ cell tumours"],"prefix":"10.1186","volume":"20","author":[{"given":"Zuzana","family":"Cierna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Miskovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Roska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Jurkovicova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia Borszekova","family":"Pulzova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzana","family":"Sestakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenka","family":"Hurbanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Machalekova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Chovanec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Rejlekova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Svetlovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Kalavska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karol","family":"Kajo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Babal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jozef","family":"Mardiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Mego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9120-5084","authenticated-orcid":false,"given":"Miroslav","family":"Chovanec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,6]]},"reference":[{"issue":"5","key":"6496_CR1","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/1097-0142(19910301)67:5<1305::AID-CNCR2820670506>3.0.CO;2-J","volume":"67","author":"RJ Motzer","year":"1991","unstructured":"Motzer RJ, Geller NL, Tan CC, Herr H, Morse M, Fair W, Sheinfeld J, Sogani P, Russo P, Bosl GJ. Salvage chemotherapy for patients with germ cell tumors. The Memorial Sloan-Kettering Cancer Center experience (1979-1989). Cancer. 1991;67(5):1305\u201310.","journal-title":"Cancer."},{"issue":"10","key":"6496_CR2","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1002\/1097-0142(19930515)71:10<3182::AID-CNCR2820711046>3.0.CO;2-O","volume":"71","author":"LH Einhorn","year":"1993","unstructured":"Einhorn LH. General motors Cancer research prizewinners laureates lectures. Charles F. Kettering prize. Clinical trials in testicular cancer. Cancer. 1993;71(10):3182\u20134.","journal-title":"Cancer."},{"issue":"12","key":"6496_CR3","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1200\/JCO.2000.18.12.2413","volume":"18","author":"RJ Motzer","year":"2000","unstructured":"Motzer RJ, Sheinfeld J, Mazumdar M, Bains M, Mariani T, Bacik J, Bajorin D, Bosl GJ. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol. 2000;18(12):2413\u20138.","journal-title":"J Clin Oncol"},{"issue":"3","key":"6496_CR4","first-page":"243","volume":"52","author":"J Mardiak","year":"2005","unstructured":"Mardiak J, Salek T, Sycova-Mila Z, Obertova J, Hlavata Z, Mego M, Reckova M, Koza I. Gemcitabine plus cisplatine and paclitaxel (GCP) in second-line treatment of germ cell tumors (GCT): a phase II study. Neoplasma. 2005;52(3):243\u20137.","journal-title":"Neoplasma"},{"issue":"6","key":"6496_CR5","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/cncr.21742","volume":"106","author":"C Kollmannsberger","year":"2006","unstructured":"Kollmannsberger C, Nichols C, Bokemeyer C. Recent advances in management of patients with platinum-refractory testicular germ cell tumors. Cancer. 2006;106(6):1217\u201326.","journal-title":"Cancer."},{"issue":"Suppl 10","key":"6496_CR6","doi-asserted-by":"crossref","first-page":"x342","DOI":"10.1093\/annonc\/mds306","volume":"23","author":"M Cullen","year":"2012","unstructured":"Cullen M. Surveillance or adjuvant treatments in stage 1 testis germ-cell tumours. Ann Oncol. 2012;23(Suppl 10):x342\u20138.","journal-title":"Ann Oncol"},{"issue":"5","key":"6496_CR7","doi-asserted-by":"crossref","first-page":"641","DOI":"10.2165\/00003495-200666050-00005","volume":"66","author":"HG Kopp","year":"2006","unstructured":"Kopp HG, Kuczyk M, Classen J, Stenzl A, Kanz L, Mayer F, Bamberg M, Hartmann JT. Advances in the treatment of testicular cancer. Drugs. 2006;66(5):641\u201359.","journal-title":"Drugs"},{"issue":"12","key":"6496_CR8","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3727\/095535490820873949","volume":"2","author":"PM O'Connor","year":"1990","unstructured":"O'Connor PM, Kohn KW. Comparative pharmacokinetics of DNA lesion formation and removal following treatment of L1210 cells with nitrogen mustard. Cancer Com. 1990;2(12):387\u201394.","journal-title":"Cancer Com"},{"key":"6496_CR9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ceb.2015.09.002","volume":"37","author":"JP Duxin","year":"2015","unstructured":"Duxin JP, Walter JC. What is the DNA repair defect underlying Fanconi anemia? Curr Opin Cell Biol. 2015;37:49\u201360.","journal-title":"Curr Opin Cell Biol"},{"issue":"10","key":"6496_CR10","doi-asserted-by":"crossref","first-page":"a012609","DOI":"10.1101\/cshperspect.a012609","volume":"5","author":"OD Sch\u00e4rer","year":"2013","unstructured":"Sch\u00e4rer OD. Nucleotide excision repair in eukaryotes. Cold Spring Harb Perspect Biol. 2013;5(10):a012609.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"6496_CR11","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.dnarep.2016.05.018","volume":"44","author":"N Sugitani","year":"2016","unstructured":"Sugitani N, Sivley RM, Perry KE, Capra JA, Chazin WJ. XPA: a key scaffold for human nucleotide excision repair. DNA Repair (Amst). 2016;44:123\u201335.","journal-title":"DNA Repair (Amst)"},{"key":"6496_CR12","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.dnarep.2015.09.003","volume":"36","author":"G Spivak","year":"2015","unstructured":"Spivak G. Nucleotide excision repair in humans. DNA Repair (Amst). 2015;36:13\u20138.","journal-title":"DNA Repair (Amst)"},{"issue":"12","key":"6496_CR13","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1214271","volume":"368","author":"L Friboulet","year":"2013","unstructured":"Friboulet L, Olaussen KA, Pignon JP, Shepherd FA, Tsao MS, Graziano S, Kratzke R, Douillard JY, Seymour L, Pirker R, et al. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med. 2013;368(12):1101\u201310.","journal-title":"N Engl J Med"},{"issue":"13","key":"6496_CR14","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1158\/1078-0432.CCR-07-0252","volume":"13","author":"A Handra-Luca","year":"2007","unstructured":"Handra-Luca A, Hernandez J, Mountzios G, Taranchon E, Lacau-St-Guily J, Soria JC, Fouret P. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clin Cancer Res. 2007;13(13):3855\u20139.","journal-title":"Clin Cancer Res"},{"issue":"19","key":"6496_CR15","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1093\/jnci\/84.19.1512","volume":"84","author":"MD Dabholkar","year":"1992","unstructured":"Dabholkar MD, Bostick-Bruton F, Weber C, Bohr VA, Egwuagu C, Reed E. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Nat Cancer Inst. 1992;84(19):1512\u20137.","journal-title":"J Nat Cancer Inst"},{"issue":"1","key":"6496_CR16","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1200\/JCO.1998.16.1.309","volume":"16","author":"R Metzger","year":"1998","unstructured":"Metzger R, Leichman CG, Danenberg KD, Danenberg PV, Lenz HJ, Hayashi K, Groshen S, Salonga D, Cohen H, Laine L, et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol. 1998;16(1):309\u201316.","journal-title":"J Clin Oncol"},{"issue":"3","key":"6496_CR17","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1093\/annonc\/mdl435","volume":"18","author":"J Bellmunt","year":"2007","unstructured":"Bellmunt J, Paz-Ares L, Cuello M, Cecere FL, Albiol S, Guillem V, Gallardo E, Charles J, Mendez P, de la Cruz JJ, et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol. 2007;18(3):522\u20138.","journal-title":"Ann Oncol"},{"issue":"1","key":"6496_CR18","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/bjc.2013.303","volume":"109","author":"J Mendoza","year":"2013","unstructured":"Mendoza J, Martinez J, Hernandez C, Perez-Montiel D, Castro C, Fabian-Morales E, Santibanez M, Gonzales-Barrios R, Diaz-Chavez J, Andonegui MA, et al. Association between ERCC1 and XPA expression and polymorphisms and the response to cisplatin in testicular germ cell tumours. Br J Cancer. 2013;109(1):68\u201375.","journal-title":"Br J Cancer"},{"issue":"1","key":"6496_CR19","first-page":"223","volume":"23","author":"B K\u00f6berle","year":"2010","unstructured":"K\u00f6berle B, Brenner W, Albers A, Usanova S, Thuroff JW, Kaina B. ERCC1 and XPF expression in human testicular germ cell tumors. Oncol Rep. 2010;23(1):223\u20137.","journal-title":"Oncol Rep"},{"issue":"10","key":"6496_CR20","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1097\/01.LAB.0000090221.95883.41","volume":"83","author":"F Honecker","year":"2003","unstructured":"Honecker F, Mayer F, Stoop H, Oosterhuis JW, Koch S, Bokemeyer C, Looijenga LH. Xeroderma pigmentosum group a protein and chemotherapy resistance in human germ cell tumors. Lab Investig. 2003;83(10):1489\u201395.","journal-title":"Lab Investig"},{"issue":"3","key":"6496_CR21","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/ijc.20134","volume":"110","author":"C Welsh","year":"2004","unstructured":"Welsh C, Day R, McGurk C, Masters JR, Wood RD, K\u00f6berle B. Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines. Int J Cancer. 2004;110(3):352\u201361.","journal-title":"Int J Cancer"},{"issue":"5","key":"6496_CR22","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0960-9822(99)80118-3","volume":"9","author":"B K\u00f6berle","year":"1999","unstructured":"K\u00f6berle B, Masters JRW, Hartley JA, Wood RD. Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr Biol. 1999;9(5):273\u20136.","journal-title":"Curr Biol"},{"issue":"2","key":"6496_CR23","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1159\/000092324","volume":"27","author":"T Mueller","year":"2006","unstructured":"Mueller T, Mueller LP, Luetzkendorf J, Voigt W, Simon H, Schmoll HJ. Loss of Oct-3\/4 expression in embryonal carcinoma cells is associated with induction of cisplatin resistance. Tumour Biol. 2006;27(2):71\u201383.","journal-title":"Tumour Biol"},{"issue":"6","key":"6496_CR24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178930","volume":"12","author":"J Schaffrath","year":"2017","unstructured":"Schaffrath J, Schmoll HJ, Voigt W, Muller LP, Muller-Tidow C, Mueller T. Efficacy of targeted drugs in germ cell cancer cell lines with differential cisplatin sensitivity. PLoS One. 2017;12(6):e0178930.","journal-title":"PLoS One"},{"issue":"1","key":"6496_CR25","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1365-2605.1987.tb00171.x","volume":"10","author":"J Casper","year":"1987","unstructured":"Casper J, Schmoll HJ, Schnaidt U, Fonatsch C. Cell lines of human germinal cancer. Int J Androl. 1987;10(1):105\u201313.","journal-title":"Int J Androl"},{"issue":"11","key":"6496_CR26","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1002\/1097-0142(19850601)55:11<2584::AID-CNCR2820551110>3.0.CO;2-B","volume":"55","author":"NJ Vogelzang","year":"1985","unstructured":"Vogelzang NJ, Bronson D, Savino D, Vessella RL, Fraley EF. A human embryonal-yolk sac carcinoma model system in athymic mice. Cancer. 1985;55(11):2584\u201393.","journal-title":"Cancer."},{"issue":"2\u20134","key":"6496_CR27","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0045-6039(84)90064-2","volume":"15","author":"D Bronson","year":"1984","unstructured":"Bronson D, Vessella R, Fraley E. Differentiation potential of human embryonal carcinoma cell lines. Cell Differentiation. 1984;15(2\u20134):129\u201332.","journal-title":"Cell Differentiation"},{"issue":"1","key":"6496_CR28","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","volume":"70","author":"H Moch","year":"2016","unstructured":"Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO classification of tumours of the urinary system and male genital organs-part a: renal, penile, and testicular tumours. Eur Urol. 2016;70(1):93\u2013105.","journal-title":"Eur Urol"},{"key":"6496_CR29","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/1471-2407-10-151","volume":"10","author":"S Ulisse","year":"2010","unstructured":"Ulisse S, Baldini E, Mottolese M, Sentinelli S, Gargiulo P, Valentina B, Sorrenti S, Di Benedetto A, De Antoni D, D\u2019Armiento M. Increased expression of urokinase plasminogen activator and its cognate receptor in human seminomas. BMC Cancer. 2010;10:151.","journal-title":"BMC Cancer"},{"issue":"7","key":"6496_CR30","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1136\/jclinpath-2012-201088","volume":"66","author":"M Mego","year":"2013","unstructured":"Mego M, Cierna Z, Svetlovska D, Macak D, Machalekova K, Miskovska V, Chovanec M, Usakova V, Obertova J, Babal P, et al. PARP expression in germ cell tumours. J Clin Pathol. 2013;66(7):607\u201312.","journal-title":"J Clin Pathol"},{"issue":"7","key":"6496_CR31","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/j.1365-2559.2006.02412.x","volume":"48","author":"T Kirkegaard","year":"2006","unstructured":"Kirkegaard T, Edwards J, Tovey S, McGlynn LM, Krishna SN, Mukherjee R, Tam L, Munro AF, Dunne B, Bartlett JM. Observer variation in immunohistochemical analysis of protein expression, time for a change? Histopathology. 2006;48(7):787\u201394.","journal-title":"Histopathology."},{"issue":"6","key":"6496_CR32","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1158\/0008-5472.CAN-05-3403","volume":"66","author":"X Wu","year":"2006","unstructured":"Wu X, Shell SM, Yang Z, Zou Y. Phosphorylation of nucleotide excision repair factor xeroderma pigmentosum group a by ataxia telangiectasia mutated and Rad3-related-dependent checkpoint pathway promotes cell survival in response to UV irradiation. Cancer Res. 2006;66(6):2997\u20133005.","journal-title":"Cancer Res"},{"issue":"36","key":"6496_CR33","doi-asserted-by":"crossref","first-page":"24213","DOI":"10.1074\/jbc.M109.000745","volume":"284","author":"SM Shell","year":"2009","unstructured":"Shell SM, Li Z, Shkriabai N, Kvaratskhelia M, Brosey C, Serrano MA, Chazin WJ, Musich PR, Zou Y. Checkpoint kinase ATR promotes nucleotide excision repair of UV-induced DNA damage via physical interaction with xeroderma pigmentosum group a. J Biol Chem. 2009;284(36):24213\u201322.","journal-title":"J Biol Chem"},{"issue":"7","key":"6496_CR34","volume":"8","author":"Z Li","year":"2013","unstructured":"Li Z, Musich PR, Cartwright BM, Wang H, Zou Y. UV-induced nuclear import of XPA is mediated by importin-alpha4 in an ATR-dependent manner. PLoS One. 2013;8(7):e68297.","journal-title":"PLoS One"},{"issue":"1","key":"6496_CR35","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/onc.2012.539","volume":"33","author":"TH Lee","year":"2014","unstructured":"Lee TH, Park JM, Leem SH, Kang TH. Coordinated regulation of XPA stability by ATR and HERC2 during nucleotide excision repair. Oncogene. 2014;33(1):19\u201325.","journal-title":"Oncogene"},{"key":"6496_CR36","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/978-3-319-56017-5_4","volume":"996","author":"PR Musich","year":"2017","unstructured":"Musich PR, Li Z, Zou Y. Xeroderma pigmentosa group a (XPA), nucleotide excision repair and regulation by ATR in response to ultraviolet irradiation. Adv Exp Med Biol. 2017;996:41\u201354.","journal-title":"Adv Exp Med Biol"},{"issue":"49","key":"6496_CR37","doi-asserted-by":"crossref","first-page":"19025","DOI":"10.1074\/jbc.RA118.003940","volume":"293","author":"SG Jarrett","year":"2018","unstructured":"Jarrett SG, Carter KM, Bautista RM, He D, Wang C, D'Orazio JA. Sirtuin 1-mediated deacetylation of XPA DNA repair protein enhances its interaction with ATR protein and promotes cAMP-induced DNA repair of UV damage. J Biol Chem. 2018;293(49):19025\u201337.","journal-title":"J Biol Chem"},{"issue":"8","key":"6496_CR38","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/mc.20418","volume":"47","author":"B K\u00f6berle","year":"2008","unstructured":"K\u00f6berle B, Roginskaya V, Zima KS, Masters JR, Wood RD. Elevation of XPA protein level in testis tumor cells without increasing resistance to cisplatin or UV radiation. Mol Carcinog. 2008;47(8):580\u20136.","journal-title":"Mol Carcinog"},{"key":"6496_CR39","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.dnarep.2017.06.028","volume":"57","author":"M Manandhar","year":"2017","unstructured":"Manandhar M, Lowery MG, Boulware KS, Lin KH, Lu Y, Wood RD. Transcriptional consequences of XPA disruption in human cell lines. DNA Repair (Amst). 2017;57:76\u201390.","journal-title":"DNA Repair (Amst)"},{"issue":"4","key":"6496_CR40","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.cell.2014.03.026","volume":"157","author":"EF Fang","year":"2014","unstructured":"Fang EF, Scheibye-Knudsen M, Brace LE, Kassahun H, SenGupta T, Nilsen H, Mitchell JR, Croteau DL, Bohr VA. Defective mitophagy in XPA via PARP-1 hyperactivation and NAD(+)\/SIRT1 reduction. Cell. 2014;157(4):882\u201396.","journal-title":"Cell"},{"issue":"4","key":"6496_CR41","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1158\/1055-9965.EPI-17-0879","volume":"27","author":"LM Morimoto","year":"2018","unstructured":"Morimoto LM, Zava D, McGlynn KA, Stanczyk FZ, Kang AY, Ma X, Wiemels JL, Metayer C. Neonatal hormone concentrations and risk of testicular germ cell tumors (TGCT). Cancer Epidemiol Biomark Prev. 2018;27(4):488\u201395.","journal-title":"Cancer Epidemiol Biomark Prev"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6496-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-6496-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6496-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T19:06:55Z","timestamp":1609787215000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-6496-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,6]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["6496"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-6496-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,6]]},"assertion":[{"value":"13 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study (IZLO 1) was approved by the Ethics Committee of the National Cancer Institute on the 2nd of February 2010, and waiver of informed consent was granted according to the Biomedical Research Act No. 576\/2004 Z.z. of the Slovak Republic. None of the cell lines required ethics approval for its use.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All of the authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}